SRZNHealthcare · BiotechnologyThe 6 Wall Street analysts covering Surrozen, Inc. hold a median 12-month price target of $48 — +62.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 79 of 100 as at 28 Oct 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Surrozen, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (96): The shares have been drifting up relative to others.
Growth (33): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on SRZN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +62.9% from it.
Of the 20 most recent actions, 2 moved their price target up and 1 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 25 Sept 2026 | HC Wainwright & Co. | Maintains | Buy | $44 → $54 |
| 20 Aug 2026 | William Blair | Initiates | Outperform | — |
| 20 Aug 2026 | William Blair | Initiates | Outperform | — |
| 10 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | $44 |
| 10 Aug 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 7 May 2026 | HC Wainwright & Co. | Maintains | Buy | $36 → $44 |
| 7 May 2026 | HC Wainwright & Co. | Maintains | Buy | — |
| 21 Apr 2026 | TD Cowen | Initiates | Buy | — |
| 24 Mar 2026 | Cantor Fitzgerald | Reiterates | Overweight | — |
| 24 Mar 2026 | HC Wainwright & Co. | Reiterates | Buy | — |
| 19 Feb 2026 | Cantor Fitzgerald | Initiates | Overweight | — |
| 12 May 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 2 Apr 2025 | HC Wainwright & Co. | Reiterates | Buy | — |
| 30 Jan 2025 | HC Wainwright & Co. | Initiates | Buy | — |
| 3 Jan 2025 | Guggenheim | Upgrade | Buy | — |
| 29 Nov 2022 | JP Morgan | Downgrade | Underweight | — |
| 18 Nov 2022 | Guggenheim | Downgrade | Neutral | — |
| 17 Nov 2022 | B of A Securities | Downgrade | Underperform | $5.00 → $1.00 |
| 17 Oct 2022 | JP Morgan | Initiates | Neutral | — |
| 27 May 2022 | B of A Securities | Downgrade | Neutral | $5.00 |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
SRZN appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 29 Oct 2026, Surrozen, Inc. returned +116.8% against +13.1% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 83% of US stocks
Cheaper than 5% of US stocks
Cheaper than 95% of US stocks
Cheaper than 81% of US stocks
Higher than 97% of US stocks
Higher than 64% of US stocks
Higher than 11% of US stocks
Higher than 30% of US stocks
Higher than 97% of US stocks
Higher than 16% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Surrozen, Inc. has a market value of $516.6M and an enterprise value of $251.4M.
Revenue in the twelve months to 30 June 2026: $11.5M. The latest quarter grew 408.6% year on year.
Net income over the same four quarters: −$332.1M, a −2885.3% net margin.
Free cash flow in the twelve months to 30 June 2026: −$35.0M.
Trailing P/E: −0.9×; forward P/E: −7.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Surrozen, Inc. employs 44 people — $262K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
| Company | Market cap | TKN rank |
|---|---|---|
| SRZNSurrozen, Inc. | $516.6M | 79 |
| OBIOOrchestra Biomed Holdings, Inc. | $350.5M | 44 |
| RLMDRelmada Therapeutics, Inc. | $351.4M | 64 |
| ARCTArcturus Therapeutics Holdings, Inc. | $342.9M | 61 |
| CTNMContineum Therapeutics, Inc. | $354.6M | 32 |
| AVIRAtea Pharmaceuticals, Inc. | $342.5M | 74 |
| KYTXKyverna Therapeutics, Inc. | $356.0M | 36 |
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Surrozen, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Surrozen announced that it closed the second and final tranche of its March 2025 private placement of securities.
Why it matters — The announcement concerns completion of a private placement, a financing event relevant to SRZN watchers.
Surrozen announced that its Investigational New Drug application for SZN-8141, a candidate for diabetic macular edema, has become effective, allowing the program to move into clinical development. The first patient in the DUET study is expected to be dosed in the fourth quarter of 2026, and this milestone triggers the second closing of a March 2025 private placement expected to provide approximately $95.1 million in gross proceeds.
Why it matters — The effective IND clears SZN-8141 to enter clinical development for a sight-threatening ophthalmic condition and unlocks substantial additional funding for Surrozen's pipeline.
Surrozen's stock price surged after the company submitted an Investigational New Drug application to the FDA for SZN-8141, a candidate to treat diabetic macular edema. The submission marks a step forward in advancing the company's lead therapy toward clinical development.
Why it matters — The FDA submission moves Surrozen's lead candidate, SZN-8141, closer to potential clinical trials, a key development milestone for the company.
Surrozen, Inc. presented at the Morgan Stanley 24th Annual Global Healthcare Conference, and a transcript of the presentation was published by Seeking Alpha. The presentation covers the company's remarks at the conference.
Why it matters — SRZN watchers would care because the transcript provides insight into the company's own messaging and positioning as shared with investors at a major industry conference.
Surrozen announced it has submitted an Investigational New Drug (IND) application to the U.S. FDA seeking to evaluate SZN-8141, a bifunctional Wnt agonist and VEGF antagonist antibody, for the treatment of diabetic macular edema (DME).
Why it matters — The IND submission is an early regulatory milestone that advances SZN-8141, a novel candidate in Surrozen's ophthalmic pipeline, toward potential clinical testing for DME.
The 6 Wall Street analysts covering Surrozen, Inc. have a median 12-month price target of $48, with estimates ranging from $40 to $54. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 6 analysts covering Surrozen, Inc., 6 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Surrozen, Inc. 79 out of 100 across roughly 4,600 US stocks as at 28 Oct 2026. None of this is personal advice — it does not consider your circumstances.
As at 28 Oct 2026, Surrozen, Inc. ranks 79 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (96 of 100).
No one can know that. What the data says: the median 12-month target from 6 analysts implies +62.9% from the last close, and Ticker Nerd's factor model ranks Surrozen, Inc. 79 out of 100 as at 28 Oct 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Surrozen, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SRZN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $40 to $54 over the next 12 months.
Surrozen, Inc. returned +116.8% over the 12 months to 29 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.
Surrozen, Inc. is a biotechnology company focused on developing antibody-based therapeutics that selectively modulate the Wnt pathway to support tissue repair and regeneration.
The most recent item we track (GlobeNewsWire, 20 Oct 2026): "Surrozen Announces Closing of Second Tranche of March 2025 Private Placement for $95.1 Million". Surrozen announced that it closed the second and final tranche of its March 2025 private placement of securities.
Surrozen, Inc. is a biotechnology company focused on developing antibody-based therapeutics that selectively modulate the Wnt pathway to support tissue repair and regeneration. The company’s current programs are centered on ophthalmology, with candidates aimed at retinal diseases, diabetic macular edema, wet age-related macular degeneration, uveitic macular edema, Fuchs’ endothelial corneal dystrophy, and geographic atrophy. Surrozen also works on tissue-specific biologics designed to engage the body’s natural repair mechanisms in other disease areas, including the intestine, liver, lung, kidney, skin, pancreas, and central nervous system. Based in South San Francisco, California, Surrozen’s role in the market is that of a clinical-stage drug developer pursuing precision biologics for serious conditions with high unmet medical need.
CEO Mr. Craig C. Parker M.B.A. · 44 employees · United States · https://www.surrozen.com
